{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:18:23Z","timestamp":1707524303045},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,5,19]]},"DOI":"10.7759\/cureus.15116","type":"journal-article","created":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T15:04:07Z","timestamp":1621436647000},"source":"Crossref","is-referenced-by-count":1,"title":["\u201cOmental Cake\u201d in a Patient With Asbestosis Leading to the Diagnosis of Malignant Peritoneal Mesothelioma"],"prefix":"10.7759","author":[{"given":"Alejandro","family":"Garc\u00eda Mart\u00ednez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inmaculada","family":"Pav\u00f3n Guerrero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lidia","family":"Campos Gonzaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Malignant mesothelioma peritoneal: epidemiology, risk factors and, clinical presentation, diagnosis and staging","author":"Alexander HR","year":"2020","unstructured":"Alexander HR.  Malignant mesothelioma peritoneal: epidemiology, risk factors and, clinical presentation, diagnosis and staging. Post TW (ed): UpToDate, Waltham, MA; 2020."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2017.03.96","article-title":"Malignant peritoneal mesothelioma: a review","volume":"5","author":"Kim J","year":"2017","unstructured":"Kim J, Bhagwandin S, Labow DM. Malignant peritoneal mesothelioma: a review. Ann Transl Med. 2017, 5:236. 10.21037\/atm.2017.03.96","journal-title":"Ann Transl Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2020.02.011","article-title":"Peritoneal mesothelioma: PSOGI\/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up","volume":"47","author":"Kusamura S","year":"2021","unstructured":"Kusamura S, Kepenekian V, Villeneuve L, et al.. Peritoneal mesothelioma: PSOGI\/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Eur J Surg Oncol. 2021, 47:36-59. 10.1016\/j.ejso.2020.02.011","journal-title":"Eur J Surg Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr.2018.10.04","article-title":"Malignan peritoneal mesothelioma: a review","volume":"7","author":"Broeckx G","year":"2018","unstructured":"Broeckx G, Pauwels P. Malignan peritoneal mesothelioma: a review. Transl Lung Cancer Res. 2018, 7:537-42. 10.21037\/tlcr.2018.10.04","journal-title":"Transl Lung Cancer Res"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.path.2019.10.001","article-title":"Diagnosis of mesothelioma","volume":"13","author":"Fels Elliott DR","year":"2020","unstructured":"Fels Elliott DR, Jones KD. Diagnosis of mesothelioma. Surg Pathol Clin. 2020, 13:73-89. 10.1016\/j.path.2019.10.001","journal-title":"Surg Pathol Clin"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21572","article-title":"Mesothelioma: scientific clues for prevention, diagnosis, and therapy","volume":"69","author":"Carbone M","year":"2019","unstructured":"Carbone M, Adusumilli PS, Alexander HR Jr, et al.. Mesothelioma: scientific clues for prevention, diagnosis, and therapy. CA Cancer J Clin. 2019, 69:402-29. 10.3322\/caac.21572","journal-title":"CA Cancer J Clin"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-019-0347-0","article-title":"Malignant mesothelioma in situ: morphologic features and clinical outcome","volume":"33","author":"Churg A","year":"2020","unstructured":"Churg A, Galateau-Salle F, Roden AC, et al.. Malignant mesothelioma in situ: morphologic features and clinical outcome. Mod Pathol. 2020, 33:297-302. 10.1038\/s41379-019-0347-0","journal-title":"Mod Pathol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr.2019.12.15","article-title":"Peritoneal mesothelioma","volume":"9","author":"Greenbaum A","year":"2020","unstructured":"Greenbaum A, Alexander HR. Peritoneal mesothelioma. Transl Lung Cancer Res. 2020, 9:S120-32. 10.21037\/tlcr.2019.12.15","journal-title":"Transl Lung Cancer Res"},{"key":"ref9","article-title":"Malignant peritoneal mesothelioma: treatment","author":"Alexander HR","year":"2019","unstructured":"Alexander HR, Kindler HL, Nowak AK. Malignant peritoneal mesothelioma: treatment. Post TW (ed): UpToDate, Waltham, MA; 2019."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr477","article-title":"Importance of gender in diffuse malignant peritoneal mesothelioma","volume":"23","author":"Cao C","year":"2012","unstructured":"Cao C, Yan TD, Deraco M, et al.. Importance of gender in diffuse malignant peritoneal mesothelioma. Ann Oncol. 2012, 23:1494-8. 10.1093\/annonc\/mdr477","journal-title":"Ann Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S170300","article-title":"Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: patient selection and special considerations","volume":"11","author":"Enomoto LM","year":"2019","unstructured":"Enomoto LM, Shen P, Levine EA, Votanopoulos KI. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: patient selection and special considerations. Cancer Manag Res. 2019, 11:4231-4. 10.2147\/CMAR.S170300","journal-title":"Cancer Manag Res"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.9012","article-title":"Nintedanib plus pemetrexed\/cisplatin in patients with malignant pleural mesothelioma: phase II results from the randomized, placebo-controlled LUME-Meso trial","volume":"35","author":"Grosso F","year":"2017","unstructured":"Grosso F, Steele N, Novello S, et al.. Nintedanib plus pemetrexed\/cisplatin in patients with malignant pleural mesothelioma: phase II results from the randomized, placebo-controlled LUME-Meso trial. J Clin Oncol. 2017, 35:3591-600. 10.1200\/JCO.2017.72.9012","journal-title":"J Clin Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.20524\/aog.2018.0305","article-title":"Malignant peritoneal mesothelioma: clinical aspects, and therapeutic perspectives","volume":"31","author":"Boussios S","year":"2018","unstructured":"Boussios S, Moschetta M, Karathanasi A, et al.. Malignant peritoneal mesothelioma: clinical aspects, and therapeutic perspectives. Ann Gastroenterol. 2018, 31:659-69. 10.20524\/aog.2018.0305","journal-title":"Ann Gastroenterol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/58243-omental-cake-in-a-patient-with-asbestosis-leading-to-the-diagnosis-of-malignant-peritoneal-mesothelioma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:33:46Z","timestamp":1707507226000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/58243-omental-cake-in-a-patient-with-asbestosis-leading-to-the-diagnosis-of-malignant-peritoneal-mesothelioma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,19]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.15116","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5,19]]}}}